| abstract |
PROBLEM TO BE SOLVED: To evaluate or monitor the therapeutic effect, efficacy and responsiveness of a therapeutic agent such as an integrin beta7 antagonist for the treatment of gastrointestinal inflammatory disorders, and / or to determine the dose or administration regimen of the therapeutic agent. Offer. SOLUTION: The amount of biomarkers in a sample obtained from a patient after or during treatment with an integrin beta7 antagonist or the like is compared with the amount of biomarkers in a sample obtained from a patient before treatment. Changes in the amount of biomarkers after or during treatment, including before treatment, indicate the effectiveness of the antagonist for the treatment of gastrointestinal disorders in the patient, or have one or more efficacy. The change when combined with a plurality of other biomarkers indicates the efficacy, and the biomarker is the gene expression level of one or more lymphocyte genes, or the gene expression level of one or more cytokines. , Or the number of alpha E-positive cells in the intestinal crypt epithelium, method. [Selection diagram] FIG. 7 |